欧林生物(688319) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥87,490,281.98, representing a 23.58% increase compared to ¥70,798,700.81 in the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥7,073,911.78, an improvement from a loss of ¥25,996,930.16 in the previous year[3]. - The company reported a net loss of CNY 102,967,913.16 for Q1 2025, compared to a net loss of CNY 95,894,001.38 in Q1 2024[11]. - The net profit for the first quarter of 2025 was -7,041,533.34 RMB, compared to -27,295,829.82 RMB in the same period of 2024, indicating an improvement[14]. - The basic earnings per share for the first quarter of 2025 was -0.0174 RMB, compared to -0.0641 RMB in the first quarter of 2024[15]. - The company reported a total comprehensive loss of -7,041,533.34 RMB for the first quarter of 2025, compared to -27,295,829.82 RMB in the same period of 2024[14]. Cash Flow - The cash flow from operating activities showed a net outflow of ¥23,503,875.42, reduced from ¥65,394,362.43 in the same period last year[3]. - Cash flow from operating activities for Q1 2025 was -23,503,875.42 RMB, an improvement from -65,394,362.43 RMB in Q1 2024[16]. - Total cash inflow from operating activities was 111,698,403.04 RMB, up from 91,177,236.11 RMB year-over-year[16]. - Cash outflow from operating activities decreased to 135,202,278.46 RMB from 156,571,598.54 RMB in the previous year[16]. - The net cash flow from investing activities was -23,418,257.22 RMB, compared to -67,309,922.57 RMB in Q1 2024, showing a significant reduction in losses[17]. - Cash inflow from financing activities was 45,000,000.00 RMB, down from 67,773,800.00 RMB in the same quarter of 2024[17]. - The net cash flow from financing activities was 14,238,783.76 RMB, a decrease from 63,953,060.05 RMB in Q1 2024[17]. - The ending cash and cash equivalents balance for Q1 2025 was 185,093,482.13 RMB, down from 286,783,648.23 RMB in Q1 2024[17]. Research and Development - Research and development (R&D) expenses totaled ¥31,518,439.71, a decrease of 49.28% from ¥62,139,896.94 year-on-year[4]. - R&D expenses accounted for 36.03% of operating revenue, down 51.74 percentage points from 87.77% in the previous year[4]. - Research and development expenses for Q1 2025 were CNY 29,123,911.81, down 39.1% from CNY 47,738,722.74 in Q1 2024[13]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,774,030,198.21, a decrease of 1.83% from ¥1,807,043,409.52 at the end of the previous year[4]. - Total assets as of March 31, 2025, were CNY 1,774,030,198.21, down from CNY 1,807,043,409.52 at the end of 2024, a decrease of 1.8%[12]. - Total liabilities decreased to CNY 845,660,471.84 as of March 31, 2025, from CNY 873,541,187.90 at the end of 2024, a reduction of 3.2%[11]. - The company’s total equity as of March 31, 2025, was CNY 928,369,726.37, a slight decrease from CNY 933,502,221.62 at the end of 2024[12]. Shareholder Information - The company had a total of 6,219 ordinary shareholders at the end of the reporting period[7]. - The largest shareholder, Shanghai Wushan Biotechnology Co., Ltd., held 72,394,330 shares, accounting for 17.83% of total shares[8]. Government Subsidies - The company reported a total of ¥4,297,791.76 in government subsidies recognized in the current period[5].